The nonhuman primate as a model for type 2 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 2, 2014, Pages 89-94

  Pound, Lynley D ^a   Kievit, Paul ^a   Grove, Kevin L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

fibroblast growth factor 21; glucagon like peptide 1; melanocortin 4 receptor; nonhuman primate; type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBROBLAST GROWTH FACTOR 21; FRUCTOSE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LY 2112688; MELANOCORTIN 4 RECEPTOR; RM 493; UNCLASSIFIED DRUG;

BASAL METABOLIC RATE; CARDIOVASCULAR EFFECT; DIET; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREATITIS; PRIMATE; REVIEW; RODENT MODEL; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MACACA MULATTA; MALE; PANCREATITIS; WEIGHT LOSS;

EID: 84896817792     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000043     Document Type: Review

References (45)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States; 2011
2. Cabrera O, Berman DM, Kenyon NS, et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 2006; 103:2334-2339
3. Brissova M, Fowler MJ, Nicholson WE, et al. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 2005; 53:1087-1097
4. Syvanen S, Lindhe O, Palner M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009; 37:635-643
5. Harwood HJ Jr, Listrani P, Wagner JD. Nonhuman primates and other animal models in diabetes research. J Diab Sci Technol 2012; 6:503-514
6. Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013; 62:490-497
7. Greenhill C. Obesity: Novel melanocortin 4 receptor agonist causes weight loss in obese rhesus macaques. Nat Rev Endocrinol 2012; 8:694
8. Bremer AA, Stanhope KL, Graham JL, et al. Fructose-fed rhesus monkeys: A nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci 2011; 4:243-252
9. Kavanagh K, Wylie AT, Tucker KL, et al. Dietary fructose induces endotoxemia and hepatic injury in calorically controlled primates. Am J Clin Nutr 2013; 98:349-357
10. Nygaard EB, Moller CL, Kievit P, et al. Increased fibroblast growth factor 21 expression in high-fat diet-sensitive nonhuman primates (Macaca mulatta). Int J Obesity 2013. doi:10.1038/ijo.2013.79.levels and alters FGF-21 and FGF-21 receptor expression in a tissue-dependent manner
11. Li S, Kievit P, Robertson AK, et al. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese rhesus macaques. Mol Metab 2013; 2:256-269
12. Jones PJ, Pappu AS, Hatcher L, et al. Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler Thromb Vasc Biol 1996; 16:1222-1228
13. Hansen BC, Newcomb JD, Chen R, Linden EH. Longitudinal dynamics of body weight change in the development of type 2 diabetes. Obesity 2013; 21:1643-1649
14. Guardado-Mendoza R, Jimenez-Ceja L, Majluf-Cruz A, et al. Impact of obesity severity and duration on pancreatic beta-And alpha-cell dynamics in normoglycemic nonhuman primates. Int J Obesity 2013; 37:1071-1078
15. Wang X, Hansen BC, Shi D, et al. Quantification of beta-cell insulin secretory function using a graded glucose infusion with C-peptide deconvolution in dysmetabolic, and diabetic cynomolgus monkeys. Diabetol Metab Syndr 2013; 5:40
16. Dai C, Brissova M, Hang Y, et al. Islet-enriched gene expression and glucoseinduced insulin secretion in human and mouse islets. Diabetologia 2012; 55:707-718
17. Mueller KR, Balamurugan AN, Cline GW, et al. Differences in glucosestimulated insulin secretion in vitro of islets from human, nonhuman primate, and porcine origin. Xenotransplantation 2013; 20:75-81
18. Veniant MM, Komorowski R, Chen P, et al. Long-Acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012; 153:4192-4203
19. Kharitonenkov A, Beals JM, Micanovic R, et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 2013; 8:e58575
20. Iglesias P, Selgas R, Romero S, Diez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 2012; 167:301-309
21. Zhao Y, Dunbar JD, Kharitonenkov A. FGF21 as a therapeutic reagent. Adv Exp Med Biol 2012; 728:214-228
22. Foltz IN, Hu S, King C, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med 2012; 4:162ra153
23. Adams AC, Halstead CA, Hansen BC, et al. LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PLoS One 2013; 8:e65763
24. Smith R, Duguay A, Bakker A, et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-Klotho bispecific protein. PLoS One 2013; 8:e61432
25. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148:774-781
26. Hecht R, Li YS, Sun J, et al. Rationale-based engineering of a potent longacting FGF21 analog for the treatment of type 2 diabetes. PLoS One 2012; 7:e49345
27. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18:333-340
28. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57:1246-1253
29. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59:2781-2789
30. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005-2012
31. Mul JD, van Boxtel R, Bergen DJ, et al. Melanocortin receptor 4 deficiency affects body weight regulation, grooming behavior, and substrate preference in the rat. Obesity 2012; 20:612-621
32. Poggioli R, Vergoni AV, Bertolini A. ACTH-(1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate agonists. Peptides 1986; 7:843-848
33. McMinn JE, Wilkinson CW, Havel PJ, et al. Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 2000; 279:R695-703
34. Koegler FH, Grove KL, Schiffmacher A, et al. Central melanocortin receptors mediate changes in food intake in the rhesus macaque. Endocrinology 2001; 142:2586-2592
35. Cowley MA, Pronchuk N, Fan W, et al. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: Evidence of a cellular basis for the adipostat. Neuron 1999; 24:155-163
36. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009; 360:44-52
37. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47
38. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: A case report. Diabetes Care 2006; 29:471
39. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. New Engl J Med 2008; 358:1969-1970
40. Tripathy NR, Basha S, Jain R, et al. Exenatide and acute pancreatitis. J Assoc Phys India 2008; 56:987-988
41. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25:1019-1027
42. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62:2595-2604
43. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Intern Med 2013; 173:534-539
44. Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: Evidence for the absence of structural pancreatic changes in three species. Diabetes 2012; 61:1243-1249
45. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care 2009; 32:834-838